PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

Evolocumab prevents carotid artery wall thickening in paediatric HeFH PCSK9 plays critical role in abdominal aortic aneurysm Post hoc analysis: alirocumab benefits HeFH and T3HLP patients Results from the German MILOS cohort demonstrate real-world effectiveness and safety of bempedoic acid PCSK9 inhibitors are unlikely to contribute to mood disorders PCSK9 inhibitors may be effective treatment for PAD

Latest News Updates

Education & Resources

Slides

Innovative immunotherapy for hypercholesterolaemia

Innovative immunotherapy for hypercholesterolaemia

PCSK9 as a therapeutic target to reduce LDL-C and the burden of ASCVD

PCSK9 as a therapeutic target to reduce LDL-C and the burden of ASCVD

Unmet clinical needs in lipid lowering: Focus on LDL-C

Unmet clinical needs in lipid lowering: Focus on LDL-C

Inclisiran and the ORION clinical development program

Inclisiran and the ORION clinical development program

PCSK9 inhibition: an overview of therapeutic approaches

PCSK9 inhibition: an overview of therapeutic approaches View all slides »

Videos

Play

Lerodalcibep: What does LIBerate-HeFH tell us?

Lerodalcibep: What does LIBerate-HeFH tell us?

Play

Verve-101: Where are we up to with PCSK9 gene editing?

Verve-101: Where are we up to with PCSK9 gene editing?

Play

Apo(a) size and PAD revascularisation outcomes: What’s the link?

Apo(a) size and PAD revascularisation outcomes: What’s the link?

Play

Lepodisiran: What progress towards Lp(a) reduction?

Lepodisiran: What progress towards Lp(a) reduction?

View all videos »

Events

American College of Cardiology Scientific Sessions 2025
Event start date: 29 Mar 2025
Chicago, USA

93rd European Atherosclerosis Society Congress 2025
Event start date: 4 May 2025
Glasgow, UK

European Society of Cardiology Congress 2025 with World Congress of Cardiology
Event start date: 29 Aug 2025
Madrid, Spain, and online

View all events »

Trials

View all trials »

Links

View all links »

Guidelines & Consensus Guidance

View all guidelines »

Archived articles

View the archive »

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation

LIB Therapeutics

Novartis

Sanofi

© Copyright 2025 PCSK9 Forum. All rights reserved